Silicon opens laboratory facilities in San Diego
The combined offices and laboratories will allow the company to leverage the capabilities of the DEPArray system in the recovery of single pure cells by offering a rare
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The harmful active pharmaceutical ingredients include diclofenac sodium and methocarbamol. Reumofan Plus, labeled in Spanish, is used for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions.